Premium
CHEMOTHERAPY FOR SMALL CELL LUNG CANCER: INPUCTION AND REINDUCTION WITH VOCA
Author(s) -
STUARTHARRIS R.,
RAGHAVAN D.,
FOX R. H.,
PERETZ G.,
CROMBIE C.,
TERIA.,
YOUNG I.,
BYE P.,
TIVER K.,
GREEN D.
Publication year - 1987
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1987.tb01225.x
Subject(s) - medicine , vincristine , nausea , cyclophosphamide , chemotherapy , vomiting , prophylactic cranial irradiation , regimen , lung cancer , oncology , surgery , myocardial infarction , conventional pci
Sixty‐five patients with small cell lung cancer were treated with VP16, vincristine, cyclophosphamide, and doxorubicin (VOCA) intravenously at three‐week intervals. Patients with limited disease received four cycles with responders receiving radiation to the primary site and prophylactic cranial irradiation. Patients with extensive disease received chemotherapy only. Of 59 patients evaluable for chemotherapy response, eight (14%) achieved complete remission and 30 (51%) partial remission. Major side‐effects included myelosuppression, alopecia, nausea, and vomiting. Reinduction with VOCA at relapse yielded objective or subjective response in four of seven patients. This regimen is active in small cell lung cancer and was well tolerated by patients. Reinduction of resDonse was Dossible in a small number of Datients retreated and mav provide useful palhation for those who relapse when treatment is discontinued.